Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luana Calabrò

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Seminars in Oncology|May 13, 2015
Immune checkpoint blockade in malignant mesotheliomaLuana Calabrò, Michele Maio
Oncoimmunology|April 16, 2014
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?Luana Calabrò, Michele Maio
The Lancet. Respiratory Medicine|May 20, 2019
The future of mesothelioma treatment: time to shift gearMichele Maio, Luana Calabrò
The Lancet. Oncology|January 4, 2014
Biomarkers for immune checkpoint inhibitors--authors' replyLuana Calabrò, Michele Maio
Journal of Thoracic Disease|March 7, 2018
New horizons from immunotherapy in malignant pleural mesotheliomaLuana Calabrò, Giulia Rossi, Michele Maio
Seminars in Oncology|November 16, 2010
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indicationsLuana Calabrò, Riccardo Danielli, Luca Sigalotti, et al.
Frontiers in Oncology|January 24, 2024
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitorsGiuseppe Bronte, Alessia Belloni, Luana Calabrò, et al.
Current Oncology Reports|October 22, 2021
COVID and Lung CancerLuana Calabrò, Giulia Rossi, Alessia Covre, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2018
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challengeLuana Calabrò, Aldo Morra, Robin Cornelissen, et al.
Clinical and Experimental Medicine|November 19, 2022
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysisGiuseppe Bronte, Luana Calabrò, Fabiola Olivieri, et al.
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Seminars in Oncology|May 13, 2015
Immune checkpoint blockade in malignant mesotheliomaLuana Calabrò, Michele Maio
Oncoimmunology|April 16, 2014
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?Luana Calabrò, Michele Maio
The Lancet. Respiratory Medicine|May 20, 2019
The future of mesothelioma treatment: time to shift gearMichele Maio, Luana Calabrò
The Lancet. Oncology|January 4, 2014
Biomarkers for immune checkpoint inhibitors--authors' replyLuana Calabrò, Michele Maio
Journal of Thoracic Disease|March 7, 2018
New horizons from immunotherapy in malignant pleural mesotheliomaLuana Calabrò, Giulia Rossi, Michele Maio
Seminars in Oncology|November 16, 2010
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indicationsLuana Calabrò, Riccardo Danielli, Luca Sigalotti, et al.
Frontiers in Oncology|January 24, 2024
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitorsGiuseppe Bronte, Alessia Belloni, Luana Calabrò, et al.
Current Oncology Reports|October 22, 2021
COVID and Lung CancerLuana Calabrò, Giulia Rossi, Alessia Covre, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2018
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challengeLuana Calabrò, Aldo Morra, Robin Cornelissen, et al.
Clinical and Experimental Medicine|November 19, 2022
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysisGiuseppe Bronte, Luana Calabrò, Fabiola Olivieri, et al.
Pageof 9